Charles D. Hyman’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Charles D. Hyman’s Portfolio GNMX Stock Details GNMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-15,143	Closed	-$19K	–	181
2018 Q3	$19K	Hold	15,143	–	–	﹤0.01%	180
2018 Q2	$17K	Hold	15,143	–	–	﹤0.01%	176
2018 Q1	$30K	Hold	15,143	–	–	﹤0.01%	176
2017 Q4	$18K	Hold	15,143	–	–	﹤0.01%	168
2017 Q3	$19K	Hold	15,143	–	–	﹤0.01%	158
2017 Q2	$20K	Hold	15,143	–	–	﹤0.01%	155
2017 Q1	$28K	Hold	15,143	–	–	﹤0.01%	145
2016 Q4	$78K	Hold	15,143	–	–	0.01%	139
2016 Q3	$84K	Hold	15,143	–	–	0.01%	138
2016 Q2	$84K	Hold	15,143	–	–	0.01%	139
2016 Q1	$67K	Hold	15,143	–	–	0.01%	137
2015 Q4	$91K	Buy	15,143 +2,143	+16%	+$14.6K	0.02%	138
2015 Q3	$102K	Hold	13,000	–	–	0.02%	141
2015 Q2	$80K	Hold	13,000	–	–	0.01%	145
2015 Q1	$105K	Hold	13,000	–	–	0.02%	144
2014 Q4	$66K	Sell	13,000 -1,500	-10%	-$7.41K	0.01%	144
2014 Q3	$75K	Hold	14,500	–	–	0.01%	141
2014 Q2	$113K	Hold	14,500	–	–	0.02%	143
2014 Q1	$101K	Hold	14,500	–	–	0.02%	140
2013 Q4	$87K	Hold	14,500	–	–	0.02%	138
2013 Q3	$113K	Hold	14,500	–	–	0.02%	136
2013 Q2	$55K	Buy	+14,500	New	+$59.4K	0.01%	136

Other funds holding GNMX

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Charles D. Hyman's GNMX Position: Q4 2018 in Review

Charles D. Hyman sold out of Aevi Genomic Medicine Inc (GNMX) in Q4 2018, closing a stake of 15,143 shares — an estimated $19K sold.

Charles D. Hyman first reported a position in GNMX in Q2 2013 and held it in 22 quarters. The position peaked at $113K in Q2 2014. 38 funds tracked by Wall St. Rank hold GNMX as of Q4 2018.

Charles D. Hyman reported no remaining Aevi Genomic Medicine Inc position as of Q4 2018 after selling out during the quarter.
Charles D. Hyman sold 15,143 Aevi Genomic Medicine Inc shares in Q4 2018, an estimated $19K.
Charles D. Hyman first reported a position in Aevi Genomic Medicine Inc in Q2 2013 and held it in 22 quarters.
Charles D. Hyman's Aevi Genomic Medicine Inc position peaked at $113K in Q2 2014.
38 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q4 2018.

Based on Charles D. Hyman's 13F filing for Q4 2018, filed 31 Jan 2019.